EC Number |
Inhibitors |
Structure |
---|
2.3.1.26 | (1R)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl (9Z,12E)-octadeca-9,12-dienoate |
- |
|
2.3.1.26 | (1R)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl 3-methylbutanoate |
- |
|
2.3.1.26 | (1R)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl benzoate |
- |
|
2.3.1.26 | (1R)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl butanoate |
- |
|
2.3.1.26 | (1R)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl pent-4-enoate |
- |
|
2.3.1.26 | (1R)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl pentanoate |
- |
|
2.3.1.26 | (1R)-1-(5,8-dihydroxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-4-methylpent-3-en-1-yl propanoate |
- |
|
2.3.1.26 | (1R,3R,7R)-1-[(1S)-1-hydroxypropyl]-3,7-diphenyl-6-[(1S)-1-phenylethyl]-2-oxa-6-azaspiro[3.3]heptan-5-one |
45% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested |
|
2.3.1.26 | (1R,3R,7S)-1-[(1S)-1-hydroxypropyl]-3,7-diphenyl-6-[(1S)-1-phenylethyl]-2-oxa-6-azaspiro[3.3]heptan-5-one |
66% inhibition, reference standard lovastatin, literature data reference IC50 = 0.012 mM, 0.0168 mM when concurrently tested |
|
2.3.1.26 | (1R,3R,7S)-1-[(1S)-1-hydroxypropyl]-3,7-diphenyl-6-[(1S)-1-phenylethyl]-2-oxa-6-azaspiro[3.3]heptan-5-one |
0.01 mM, 66% inhibition |
|